Cargando…
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML) from two transplantation centers in China and F...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462832/ https://www.ncbi.nlm.nih.gov/pubmed/30082853 http://dx.doi.org/10.1038/s41409-018-0283-5 |
_version_ | 1783410648197103616 |
---|---|
author | Wang, Ling Devillier, Raynier Wan, Ming Decroocq, Justine Tian, Liang Fürst, Sabine Wang, Li-Ning Vey, Norbert Fan, Xing Blaise, Didier Hu, Jiong |
author_facet | Wang, Ling Devillier, Raynier Wan, Ming Decroocq, Justine Tian, Liang Fürst, Sabine Wang, Li-Ning Vey, Norbert Fan, Xing Blaise, Didier Hu, Jiong |
author_sort | Wang, Ling |
collection | PubMed |
description | The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML) from two transplantation centers in China and France. A total of 47 refractory AML with median bone marrow blast of 35% (1–90%) and median age at 42 years (16–62) were enrolled. Thirteen patients received peripheral stem cell transplantation (HSCT) from HLA-matched sibling donor, while 18 and 16 from unrelated or haplo-identical donors, respectively. With a median follow-up of 24.3 months (1–70), 13 patients relapsed at a median time of 5.1 months (2.2–18.0) and 24 patients died due to relapse (n = 12) or non-relapsed mortality (NRM, n = 12). The estimated 3-year RR and NRM were 33.5 ± 5.7% and 25.7 ± 4.2%, respectively. The estimated 3-year overall survival (OS) and event-free survival (EFS) were 43.8 ± 7.8% and 42.3 ± 7.8%. In multivariate analysis, age (<40) and low bone marrow blast were associated with better EFS, while no difference was observed between the two centers. The patients enrolled in study were unselected, representing typical patients' population of refractory AML, and primary data demonstrated the feasibility of sequential conditioning regimen. |
format | Online Article Text |
id | pubmed-6462832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-64628322019-09-27 Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes Wang, Ling Devillier, Raynier Wan, Ming Decroocq, Justine Tian, Liang Fürst, Sabine Wang, Li-Ning Vey, Norbert Fan, Xing Blaise, Didier Hu, Jiong Bone Marrow Transplant Article The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML) from two transplantation centers in China and France. A total of 47 refractory AML with median bone marrow blast of 35% (1–90%) and median age at 42 years (16–62) were enrolled. Thirteen patients received peripheral stem cell transplantation (HSCT) from HLA-matched sibling donor, while 18 and 16 from unrelated or haplo-identical donors, respectively. With a median follow-up of 24.3 months (1–70), 13 patients relapsed at a median time of 5.1 months (2.2–18.0) and 24 patients died due to relapse (n = 12) or non-relapsed mortality (NRM, n = 12). The estimated 3-year RR and NRM were 33.5 ± 5.7% and 25.7 ± 4.2%, respectively. The estimated 3-year overall survival (OS) and event-free survival (EFS) were 43.8 ± 7.8% and 42.3 ± 7.8%. In multivariate analysis, age (<40) and low bone marrow blast were associated with better EFS, while no difference was observed between the two centers. The patients enrolled in study were unselected, representing typical patients' population of refractory AML, and primary data demonstrated the feasibility of sequential conditioning regimen. Nature Publishing Group UK 2018-08-06 2019 /pmc/articles/PMC6462832/ /pubmed/30082853 http://dx.doi.org/10.1038/s41409-018-0283-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Wang, Ling Devillier, Raynier Wan, Ming Decroocq, Justine Tian, Liang Fürst, Sabine Wang, Li-Ning Vey, Norbert Fan, Xing Blaise, Didier Hu, Jiong Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes |
title | Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes |
title_full | Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes |
title_fullStr | Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes |
title_full_unstemmed | Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes |
title_short | Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes |
title_sort | clinical outcome of flag-ida chemotherapy sequential with flu–bu3 conditioning regimen in patients with refractory aml: a parallel study from shanghai institute of hematology and institut paoli-calmettes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462832/ https://www.ncbi.nlm.nih.gov/pubmed/30082853 http://dx.doi.org/10.1038/s41409-018-0283-5 |
work_keys_str_mv | AT wangling clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT devillierraynier clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT wanming clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT decroocqjustine clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT tianliang clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT furstsabine clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT wanglining clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT veynorbert clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT fanxing clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT blaisedidier clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes AT hujiong clinicaloutcomeofflagidachemotherapysequentialwithflubu3conditioningregimeninpatientswithrefractoryamlaparallelstudyfromshanghaiinstituteofhematologyandinstitutpaolicalmettes |